Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01941056 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Healthy Volunteers With or Without Previous Exposure to Cytomegalovirus
A Phase 1 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT01941056 is a Phase 1 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 24 participants.
The verdict
NCT01941056, a Phase 1 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and the best dose of vaccine therapy in healthy volunteers with or without previous exposure to cytomegalovirus. Vaccines made from a gene-modified virus may help the body build an immune response and may help prevent cytomegalovirus infection.
Interventions
- OTHER laboratory biomarker analysis
- BIOLOGICAL multi-CMV epitope modified vaccinia Ankara vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2014-01-05 |
| Est. Completion | 2017-07-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01941056
The ClinicalTrials.gov registry entry for NCT01941056 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT01941056 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01941056 about?
NCT01941056 is a clinical study titled "Vaccine Therapy in Healthy Volunteers With or Without Previous Exposure to Cytomegalovirus". This phase I trial studies the side effects and the best dose of vaccine therapy in healthy volunteers with or without previous exposure to cytomegalovirus. Vaccines made from a gene-modified virus may help the body build an immune response and may help prevent cytomegalovirus infection.
What is the current status of trial NCT01941056?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2014-01-05. Estimated completion is 2017-07-28.
What interventions are being tested in trial NCT01941056?
The interventions under investigation include: laboratory biomarker analysis (OTHER), multi-CMV epitope modified vaccinia Ankara vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01941056?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.